Navigation Links
Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles

DEERFIELD, Ill., Feb. 15, 2011 /PRNewswire/ -- Takeda Pharmaceuticals International, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that its Pharmaceutical Development Division has entered into strategic partnerships with Covance (NYSE: CVD) and Quintiles, two of the world's largest full-service contract research organizations.

Under terms of the agreements, Covance and Quintiles will work in close partnership with Takeda to plan and execute global development programs to support new compounds in all therapeutic areas, except oncology. Takeda will have access to the clinical development capabilities and central laboratory services of Covance and Quintiles, with each partner company providing dedicated resources to support Takeda's development pipeline. Takeda intends to use a global program-level sourcing strategy to increase operational efficiency. Through these relationships, Takeda will move toward a fully virtual outsourcing model combining the expertise and capabilities of Takeda with those of Covance and Quintiles to improve productivity and facilitate Takeda's global growth.  

"Takeda is focused on growing its global drug development footprint, especially in Asia, while at the same time ensuring quality and increasing efficiency of our operations," said Robert Ahlbrandt, Ph.D., senior vice president, global development operations for Takeda's Pharmaceutical Development Division. "Our new strategic partnerships with Covance and Quintiles will improve the agility and productivity of our drug development activities, helping us to deliver innovative new medicines to patients globally."

About Takeda Pharmaceuticals International, Inc.

Located in Deerfield, Illinois, Takeda Pharmaceuticals International, Inc. is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, an industry leader and the largest pharmaceutical company in Japan. Takeda Pharmaceuticals International, Inc. is the hub for R&D excellence and the commercial activities in Americas and Europe as well as other strategic functions of Takeda group. It is committed to maximize the global market potential of new products and the company's international presence to realize Takeda's Mission to strive toward better health for patients through leading innovation in medicine. Additional information about Takeda is available through its corporate Web site,

SOURCE Takeda Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride)
2. Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S.
3. Arthritis Foundation and Takeda Launch First-Ever National Gout Public Service Announcement (PSA) Campaign, Urging People Living With Gout to Keep Enjoying Lifes Simple Pleasures
4. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
5. Takeda Responds to FDA Advisory Committee Recommendation
6. Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S.
7. CellCentric Licenses Novel Epigenetic Discovery Programme to Takeda
8. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
9. Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate)
10. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
11. Takeda San Francisco, Inc. Appoints Michael Buckley, Ph.D. Vice President of Process Sciences
Post Your Comments:
(Date:11/26/2015)... --> --> Juntendo University Hospital ... weighting of MRI for patients with Multiple Sclerosis (MS) ... with SyntheticMR in order to use SyMRI in clinical research ... generate multiple contrast images from a single scan and adjust ... it possible to both fine tune images and recreate additional ...
(Date:11/26/2015)... ) has ... Future Horizons and Growth Strategies in the ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> ) has announced the ... and Growth Strategies in the French Drugs ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... Wound Care Market by Type (Dressings, Therapy Devices, Active ... Facility, Out-Patient Facility), and Geography - Global Forecast to ... --> --> The purpose of ... forecast of the global advanced wound care market. It ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... Somu Sivaramakrishnan announced ... franchise owner, Somu now offers travelers, value and care based Travel Services, including ... sales, as well as, cabin upgrades and special amenities such as, shore excursions, ...
(Date:11/26/2015)... ... 26, 2015 , ... Pixel Film Studios brings Final Cut ... Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, with ... users limitless opportunities to stylize and create designs quickly and easily, all within ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... preparing the perfect dish and pleasing the palates of attendees is of the ... a dish to a seasonal get-together, give these recipes a try this holiday ...
(Date:11/25/2015)... ... 2015 , ... Ministers, senior government and UN agencies, representatives ... of Excellence, and public R&D institutions, civil societies and other partners gathered today ... African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- day ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would like to become more ... to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will be ... As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are ...
Breaking Medicine News(10 mins):